Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Wellbutrin
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Aplenzin
|
| gptkbp:class |
gptkb:drug
Norepinephrine-dopamine reuptake inhibitor |
| gptkbp:contraindication |
Eating disorders
Seizure disorder |
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:form |
Extended-release tablet
|
| gptkbp:has_ability |
174 mg
348 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Aplenzin
|
| gptkbp:ingredients |
gptkb:Bupropion
|
| gptkbp:is_used_for |
gptkb:Depression
|
| gptkbp:manager |
Oral
|
| gptkbp:manufacturer |
gptkb:Teva_Pharmaceuticals
|
| gptkbp:packaging |
Blister pack
|
| gptkbp:previous_name |
Bupropion hydrobromide
|
| gptkbp:requires |
Prescription only
|
| gptkbp:side_effect |
gptkb:Insomnia
gptkb:Nausea Dry mouth |